Antifibrinolytic Therapy with Cyklokapron in Connection with Prostatectomy: A Double Blind Study

Abstract

AMCA (tranexamic acid, Cyklokapron® KABI) was given intravenously according to the double blind technique to 92 non-selected patients who underwent transvesical prostatectomy. Treatment with both 3 g AMCA per day and 1.5 g per day resulted in a statistically significant reduction in post-operative bleeding. Already during the initial post-operative period when 70% of the total postoperative blood loss occurred, the reduction in bleeding was significant in the AMCA treated patient groups. Side effects were small and were reduceable still further if the preparation was administered slowly.